Nex Immune
Biotechnology, 9119 Gaither Rd, Gaithersburg, Maryland, 20877, United States, 51-200 Employees
Phone Number: 30********
Who is NEXIMMUNE
NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) tech...
Read More
-
Headquarters: 9119 Gaither Rd, Gaithersburg, Maryland, 20877, United States
-
Date Founded: 2011
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Kristi Jones
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
NexImmune Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding NexImmune
Answer: NexImmune's headquarters are located at 9119 Gaither Rd, Gaithersburg, Maryland, 20877, United States
Answer: NexImmune's phone number is 30********
Answer: NexImmune's official website is https://neximmune.com
Answer: NexImmune's revenue is $10 Million to $25 Million
Answer: NexImmune's SIC: 2834
Answer: NexImmune's NAICS: 325412
Answer: NexImmune has 51-200 employees
Answer: NexImmune is in Biotechnology
Answer: NexImmune contact info: Phone number: 30******** Website: https://neximmune.com
Answer: NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) technology. NexImmune has a differentiated platform and pipeline of product candidates in pre-clinical and phase 1/2 stages with lead programs focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune’s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities. For the last decade, the AIM platform has evolved into a stable platform for various therapy targets providing an opportunity to make a massive impact due to its adaptability and flexibility in oncology, autoimmune disorders, infectious disease, and beyond.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month